Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8+ T cell response: A comparative study

Component: Nanoparticle Core; Description: PLGA (poly(lactic-co-glycolic acid), Resomer RG 502 H, 50:50, MW 7,000-17,000 Da) — biodegradable, FDA-approved

Component: Surface Coating; Description: PEG-lipid layer: DSPE-PEG(2000) succinic acid + mPEG 2000 PE — provides stealth properties and carboxyl groups for antibody conjugation

Component: Targeting Antibodies; Description: • Anti-CD40 (clone FGK45, IgG2a) — TNF-α family receptor; activating receptor<br>• Anti-DEC-205 (CD205) — C-type lectin receptor; endocytic receptor<br>• Anti-CD11c — integrin receptor; DC-specific marker

Component: Isotype Controls; Description: IgG2a and IgG2b (non-targeting)

Component: Conjugation Chemistry; Description: EDC/NHS coupling: surface carboxyl groups activated, antibodies conjugated via amine groups; ~25-37 μg antibody/mg PLGA

Component: Payload; Description: • Antigen: Ovalbumin (OVA), endotoxin-free; 225 μg/mg NP (encapsulated)<br>• TLR3 agonist: Poly I:C (4 mg/mg NP)<br>• TLR7/8 agonist: R848 (resiquimod; 1 mg/mg NP)

Component: Nanoparticle Properties; Description: • Size: ~187-242 nm (PDI 0.064-0.234)<br>• Zeta potential: −22 to −36 mV (less negative after Ab conjugation)<br>• Spherical morphology (TEM); PEG-lipid layer visible

Component: Fluorescent Labels; Description: CW800-OVA (near-IR), Alexa-647-OVA, CFSE (T cell proliferation)

Parameter: In Vitro Studies; Details: BMDCs from WT C57BL/6 or CD40 KO mice; NP incubation at 4°C (binding) or 37°C (uptake); 1-24 h; Odyssey scanning (NIR fluorescence); flow cytometry (CD40/CD86 expression)

Parameter: DC Activation; Details: IL-12 p70 ELISA; CD40/CD86 expression by flow cytometry; Cytochalasin D inhibition of actin polymerization

Parameter: T Cell Priming (In Vitro); Details: DCs loaded with NP; co-culture with OT-I (CD8⁺) or OT-II (CD4⁺) splenocytes; ³H-thymidine proliferation; IFN-γ ELISA

Parameter: In Vivo Vaccination; Details: C57BL/6 mice; s.c. injection (tail base or right flank); 10 μg OVA per NP dose; IVIS imaging for NP clearance (0-144 h)

Parameter: OT-I T Cell Transfer; Details: Purified CD8⁺ OT-I T cells (CD90.1⁺) transferred 48 h post-vaccination; expansion measured in draining lymph nodes and spleen (day 4)

Parameter: In Vivo Cytotoxicity; Details: Day 7 post-vaccination; CFSE-labeled target cells (OVA peptide-pulsed, CFSEʰⁱ; Flu peptide control, CFSEˡᵒ); 1:1 mix injected i.v.; 18 h later; specific lysis calculated

Parameter: Controls; Details: Non-targeted NPs (isotype); no vaccination; soluble OVA + TLRs

Parameter: Replicates; Details: 2-4 mice per group; 2-3 independent experiments

Parameter: Statistical Tests; Details: Two-way ANOVA with Bonferroni post-tests; Mann-Whitney test; Student's t-test

Analysis Category: Nanoparticle Characterization; Methods: DLS (size, PDI); zeta potential (Malvern ZetaSizer); TEM (morphology); Coomassie protein assay (antibody quantification); HPLC (TLR ligand encapsulation)

Analysis Category: DC Binding/Uptake; Methods: Odyssey NIR scanning (800 nm); TO-PRO® nuclear staining (700 nm) for cell number normalization; ratio 800/700 nm

Analysis Category: DC Activation; Methods: Flow cytometry: CD40, CD86 (BD Pharmingen); IL-12 p70 ELISA (BD OptEIA)

Analysis Category: T Cell Proliferation; Methods: ³H-thymidine incorporation (16 h pulse); TopCount scintillation counter; Stimulation Index

Analysis Category: IFN-γ Production; Methods: ELISA (BD OptEIA); culture supernatants at 48 h

Analysis Category: In Vivo Imaging; Methods: IVIS Spectrum; CW800 fluorescence; ROI quantification at injection site; total radiant efficiency [p/s]/[μW/cm²]

Analysis Category: Flow Cytometry; Methods: BD LSRII; antibodies: CD8b, CD90.1, CD45.1, CD11c, CD40, CD86, F4/80, CD11b; 7-AAD for dead cells; FlowJo analysis

Analysis Category: In Vivo Cytotoxicity; Methods: CFSE dilution; CFSEʰⁱ (OVA target) vs. CFSEˡᵒ (Flu control); % specific lysis = 1 - [(OVA/FLU)_vaccinated / (OVA/FLU)_non-vaccinated] × 100%

Parameter: Size (nm); Non-Targeted: 186.6 ± 9.0; αCD40: 200.7 ± 12.5; αDEC-205: 198.2 ± 12.9; αCD11c: 194.7 ± 11.6

Parameter: PDI; Non-Targeted: 0.086 ± 0.012; αCD40: 0.109 ± 0.025; αDEC-205: 0.085 ± 0.016; αCD11c: 0.148 ± 0.068

Parameter: Zeta potential (mV); Non-Targeted: −34.4 ± 6.2; αCD40: −30.8 ± 2.3; αDEC-205: −28.8 ± 2.5; αCD11c: −30.0 ± 4.6

Parameter: Antibody conjugation (μg/mg); Non-Targeted: -; αCD40: 29.1 ± 3.1; αDEC-205: 32.0 ± 3.2; αCD11c: 25.0 ± 3.7

Parameter: OVA encapsulation; Non-Targeted: 225 μg/mg NP; αCD40: 225 μg/mg NP; αDEC-205: 225 μg/mg NP; αCD11c: 225 μg/mg NP

Target: αCD40; Binding (4°C): Highest; Uptake (37°C): Highest; Kinetic Uptake (24 h): Highest (significant difference)

Target: αDEC-205; Binding (4°C): Significantly higher; Uptake (37°C): Significantly higher; Kinetic Uptake (24 h): Significantly higher

Target: αCD11c; Binding (4°C): Significantly higher; Uptake (37°C): Significantly higher; Kinetic Uptake (24 h): Significantly higher

Target: Non-targeted; Binding (4°C): Baseline; Uptake (37°C): Baseline; Kinetic Uptake (24 h): Baseline

Treatment: Targeted NPs (CD40, DEC-205, CD11c); % Double Positive: >90%; Significance: Significant vs. controls

Treatment: Non-targeted NP; % Double Positive: ~50%; Significance: -

Treatment: Soluble components; % Double Positive: ~30%; Significance: -

Treatment: Targeted NPs; IL-12 (pg/mL): High (similar across all targets)

Treatment: Non-targeted NP; IL-12 (pg/mL): Low

Treatment: Soluble OVA + TLRs; IL-12 (pg/mL): Low

Treatment: Cytochalasin D inhibition; IL-12 (pg/mL): Marked reduction (phagocytosis-dependent uptake confirmed)

Treatment: Targeted NPs; CD8⁺ (OT-I): High (similar across targets); CD4⁺ (OT-II): High (similar across targets)

Treatment: Non-targeted NP; CD8⁺ (OT-I): Low; CD4⁺ (OT-II): Low

Treatment: Soluble components; CD8⁺ (OT-I): Low; CD4⁺ (OT-II): Low

Treatment: IFN-γ secretion; CD8⁺ (OT-I): High for targeted NPs; CD4⁺ (OT-II): High for targeted NPs

Time: 0 h; Targeted NPs: 100%; Non-Targeted NP: 100%

Time: 24 h; Targeted NPs: 40-60% remaining; Non-Targeted NP: >60% remaining

Time: 144 h (6 days); Targeted NPs: ~30% remaining; Non-Targeted NP: ~60% remaining

Time: Conclusion; Targeted NPs: Targeted NPs clear faster from injection site; Non-Targeted NP: Non-targeted NP persists

Treatment: αCD40 NP; % OT-I (CD90.1⁺) of CD8⁺: Highest

Treatment: αDEC-205 NP; % OT-I (CD90.1⁺) of CD8⁺: Intermediate

Treatment: αCD11c NP; % OT-I (CD90.1⁺) of CD8⁺: Intermediate

Treatment: Non-targeted NP; % OT-I (CD90.1⁺) of CD8⁺: Low

Treatment: Spleen; % OT-I (CD90.1⁺) of CD8⁺: Similar trend (CD40 > DEC-205 ≈ CD11c > non-targeted)

Treatment: αCD40 NP; % Specific Lysis: ~80%

Treatment: αDEC-205 NP; % Specific Lysis: ~80%

Treatment: αCD11c NP; % Specific Lysis: ~80%

Treatment: Non-targeted NP; % Specific Lysis: ~40%

Treatment: No vaccination; % Specific Lysis: ~0%

Treatment: Conclusion; % Specific Lysis: All targeted NPs equally potent for CTL induction

1. No significant differences between targeted receptors in vivo: Despite CD40 showing slightly better uptake in vitro, "no significant differences were observed in vivo between the immunological responses induced by the PLGA NP targeted to different receptors (CD40, DEC-205 or CD11c)."

2. Model antigen only: The study used OVA as a model antigen, not tumor-associated antigens; translation to therapeutic cancer vaccines was not demonstrated.

3. No tumor challenge model: While robust CTL responses were induced, the study did not show therapeutic efficacy against established tumors.

4. CD40 may have signaling effects beyond targeting: CD40 is an activating receptor, while DEC-205 and CD11c are not; the authors note that "possibly the activation by TLR ligands could be substantially higher than those induced by the receptors targeted by the PLGA NP, therefore hiding the effect of the latter."

5. In vitro DC activation from CD40 KO mice not fully explored: The study mentions CD40 KO mice but does not present detailed data on whether the enhanced uptake was CD40-dependent.

6. No assessment of antibody-dependent effects: The use of whole IgG antibodies could engage Fc receptors; while isotype controls were used, the potential contribution of FcR-mediated uptake was not fully controlled for.

7. NP biodistribution not extensively characterized: While the study showed targeted NPs cleared faster from injection sites, detailed biodistribution to organs (liver, spleen, kidney) was not the focus of the paper.

8. No therapeutic vaccine studies: The paper focuses on immune responses but does not demonstrate protection against tumor challenge or infectious disease models.

9. Human translation uncertainty: All experiments were performed in murine systems; human DC receptors differ in expression and function.

10. Potential for TLR agonist toxicity: While TLR3/7 agonists are potent adjuvants, systemic administration of encapsulated agonists could cause inflammatory side effects; these were not assessed.

11. No long-term memory studies: The study assessed primary CTL responses at day 7 but did not evaluate memory T cell formation or durability of responses.

12. Antibody conjugation variability: Antibody coupling efficiency varied between 25-37 μg/mg PLGA, which could affect reproducibility.

Report prepared based on the published Biomaterials article. For full experimental details, supplementary figures, and complete references, please refer to the original publication.